Daily Medication Pearl: Daridorexant (Quviviq)
Daridorexant (Quviviq) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Medication Pearl of the Day: Daridorexant (Quviviq)
Indication: Daridorexant (Quviviq) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Dosing: The recommended dosage is 25 mg to 50 mg once per night, taken orally within 30 minutes before going to bed, with at least 7 hours remaining prior to planned awakening.
- Dosage forms: Tablets 25 mg, 50 mg.
- Adverse events: The most common adverse reactions, reported in ≥ 5% of patients treated with daridorexant and at an incidence ≥ than placebo, were headache and somnolence or fatigue.
- Mechanism of action: The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors.The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.
- Manufacturer: Idorsia Pharma